Patent challenger Natco Pharma has made a strategic about turn and has now emerged as a licensee for Gilead Sciences's blockbuster hepatitis C therapy, Sovaldi (sofosbuvir).
Natco informed Indian bourses that it had signed a non-exclusive licensing pact with Gilead, to manufacture and sell generic versions...






